Office of the Vice-President (Research and Development)
In vivo selective cancer-tracking gadolinium eradicator as new-generation photodynamic therapy agent
© 2014, National Academy of Sciences. All rights reserved. In this work, we demonstrate a modality of photodynamic therapy (PDT) through the design of our truly dual-functional - PDT and imaging - gadolinium complex (Gd-N), which can target cancer cells specifically. In the light of our design, the PDT drug can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species - singlet oxygen - before due excitation. Comprehensive in vitro and in vivo studies had been conducted for the substantiation of the effectiveness of Gd-N as such a tumor-selective PDT photosensitizer. This treatment modality does initiate a new direction in the development of "precision medicine" in line with stem cell and gene therapies as tools in cancer therapy.
Gadolinium, Imaging, In vivo PDT, Survivin, Tumor recognition
Source Publication Title
Proceedings of the National Academy of Sciences
National Academy of Sciences
Link to Publisher's Edition
Zhang, Tao, Rongfeng Lan, Chi-Fai Chan, Ga-Lai Law, Wai-Kwok Wong, and Ka-Leung Wong. "In vivo selective cancer-tracking gadolinium eradicator as new-generation photodynamic therapy agent." Proceedings of the National Academy of Sciences 111.51 (2014): E5492-E5497.